PARP1 and neoplasm: In order to separate the effects of PARP inhibition on immunomodulation from its effects on the DNA damage repair pathway in the Trp53−/− Brca1−/− model, it would be valuable to test the treatment of these tumours with olaparib in immunodeficient mice.